US6200307B1
Expired / Lapsed
US
⏱️ 0.0 years remaining
Treatment of in-stent restenosis using cytotoxic radiation
Assignee: Illumenex Corp
•
Filing: 1998-05-22
•
Granted: 2001-03-13
•
Expires: 2018-05-22
Abstract
Abstract A method for treating in-stent restenosis using radiation having a wavelength sufficient to kill or promote cellular death (e.g., through programmed cell death), or otherwise remove smooth muscle cells which have proliferated, or which might otherwise proliferate, in the proximity of (i.e., within, around or adjacent to) a stent within a body lumen, causing (or potentially causing) at least partial blockage of the lumen. The treatment method includes irradiating smooth muscle cells in the region of the stenosis with non-ablative, cytotoxic radiation, such as UV radiation. A cytotoxic, photoactivatable chromophore may also be delivered to the treatment site prior to irradiation. The method can be used prophylactically or to treat in-stent restenosis after blockage has occurred without further damage to surrounding tissue.
Inventors
- 👤 Michael Kasinkas
- 👤 Robert A. Van Tassel
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 01:38
CPC Classifications
A; A61; A61N; A61N5/00; A61N5/06; A61N5/0601; A61B; A61B17/00; A61B17/22; A61B18/00; A61B18/18; A61B18/20; A61B18/22; A61B18/24; A61B2017/22001; A61B2017/22002; A61B2017/22051; A61B2017/22057; A61B2017/22059; A61B2017/22062; A61B2017/22064; A61B2017/22082; A61B2017/22087; A61B2018/2255; A61B2018/2261; A61N2005/0658; A61N2005/0661
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
75 words
A method of treating restenosis which has occurred in proximity to a stent that has previously been implanted in a body lumen comprising: disposing an optical waveguide means inside the body lumen containing the stent; locating the waveguide means adjacent to an area in which smooth muscle cell overgrowth in the proximity of the stent has occurred; and irradiating the area of smooth muscle cell overgrowth with non-ablative, cytotoxic radiation via said optical waveguide means.
Claim 2
Independent Claim
75 words
A method of treating restenosis which has occurred in proximity to a stent that has previously been implanted in a body lumen comprising: disposing an optical waveguide means inside the body lumen containing the stent; locating the waveguide means adjacent to an area in which smooth muscle cell overgrowth in the proximity of the stent has occurred; and irradiating the area of smooth muscle cell overgrowth with non-ablative, cytotoxic radiation via said optical waveguide means.
Claim 3
Dependent Claim
11 words
The method of claim 1 wherein the radiation is UV radiation.
Claim 4
Dependent Claim
14 words
The method of claim 2 wherein the UV radiation is low power UV radiation.
Claim 5
Dependent Claim
18 words
The method of claim 1 wherein the radiation has a wavelength of about 240 to about 280 nanometers.
Claim 6
Dependent Claim
21 words
The method of claim 2 wherein the UV radiation has power density of about 5 watts per square centimeter or less.
Claim 7
Dependent Claim
23 words
The method of claim 1 wherein the method further comprises delivering a chromophore to the area of smooth muscle overgrowth prior to irradiation.
Claim 8
Dependent Claim
12 words
The method of claim 6 wherein the chromophore is a photoactivatable psoralen.
Claim 9
Dependent Claim
20 words
The method of claim 6 wherein the radiation is selected from the group consisting of UV radiation and visible radiation.
Claim 10
Dependent Claim
49 words
The method of claim 1 wherein the step of irradiating the area of smooth muscle cell overgrowth results death of at least a portion of the cells in the area of overgrowth, resulting in decreased tissue mass and an increase in the diameter of the lumen containing the overgrowth.
Claim 11
Dependent Claim
27 words
The method of claim 1 wherein the method further comprises the step of deploying an expansion element within the stent to mechanically displace blockage within the stent.
References Cited (Backward Citations)
US4512762A
Cited
US5100429A
Cited
US5092841A
Cited
US5053033A
Cited
US5254112A
Cited
US5116864A
Cited
US5925035A
Cited
US5514707A
Cited
WO1996007451A2
Cited
US5620438A
Cited
US5591199A
Cited
US5899917A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2004-03-12 | 2004-09-11 | 2005-03-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2008-03-12 | 2008-09-11 | 2009-03-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2012-03-12 | 2012-09-11 | 2013-03-13 | $7700.00 | Window Closed / Lapsed |